查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995341

神經痛治療市場：2026年至2032年全球市場預測（依治療方法、給藥途徑、藥物類別、最終用戶、通路和適應症分類）

Neuralgia Treatment Market by Treatment Type, Delivery Mode, Drug Class, End User, Distribution Channel, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經痛治療市場價值將達到 13.5 億美元，到 2026 年將成長到 15.3 億美元，到 2032 年將達到 32.4 億美元，複合年成長率為 13.24%。

主要市場統計數據
基準年 2025 13.5億美元
預計年份：2026年 15.3億美元
預測年份 2032 32.4億美元
複合年成長率 (%) 13.24%

對當前神經痛治療領域中涉及的臨床、技術和治療方案等多方面因素進行了權威概述。

神經痛的臨床治療面臨許多挑戰，涉及慢性疼痛管理、不斷發展的醫療設備創新以及多樣化的藥物治療策略。近年來，臨床路徑不斷擴展，體現出一種更全面的治療方法，除了傳統的藥物治療外，還涵蓋了非藥物療法。臨床醫師越來越重視療效、耐受性和長期功能預後的平衡，這促使治療流程的發展和應用方式改變。本文透過檢驗臨床證據、病患偏好和醫療保健系統壓力之間的相互作用，概述了當前的治療格局，重點在於重塑臨床實踐模式和商業性利益的關鍵因素。

深入了解技術、臨床和醫療保健系統因素的融合，這些因素正在重新定義神經痛治療的治療路徑和商業性方法。

在技​​術創新、護理模式轉變以及臨床實踐中對療效日益成長的期望的推動下，神經痛的治療現狀正經歷著變革性的轉變。神經調控療法硬體和軟體的進步拓展了藥物治療以外的治療選擇，使臨床醫生能夠根據患者的表現型和疼痛病因制定個人化的干涉措施。同時，診斷準確性的提高和生物標記研究的進展有助於治療分層，從而實現早期療育和更精確的治療反應追蹤。除了這些技術變革之外，人們越來越重視多方面的治療方法，將介入治療、復健和行為療法結合，以實現持續的症狀控制和功能恢復。

從分析的觀點探討了近期關稅措施如何重組了與神經痛治療相關的供應鏈的韌性、籌資策略和商業規劃。

美國2025年實施的新關稅措施正在對神經痛治療相關醫療產品的採購、籌資策略和供應鏈設計產生影響。進口關稅和貿易調整迫使相關人員重新評估其供應商組合，優先考慮成本控制，並探索替代籌資策略，以維持專用醫療設備、藥品原料和輔助用品的持續供應。採購團隊正在加強對總到岸成本和韌性指標的評估，因此，一些製造商和經銷商正在分散其製造地，並與戰略合作夥伴重新談判合約條款，以在確保關鍵治療藥物供應的同時，緩解利潤率壓力。

從治療方法、給藥方法、最終用戶、分銷、適應症和藥物分類等方面進行策略性細分，以確定差異化的機會領域和營運重點。

多維度細分觀點揭示了不同治療類型、給藥途徑、最終用戶、分銷管道、適應症和藥物類別中清晰的機會領域和營運考慮。按治療類型分析，區分了針灸、神經調控療法和物理療法等非藥物療法與藥物療法，每種療法都有其獨特的啟動促進因素、報銷趨勢和證據要求。按給藥途徑細分，區分了注射劑、口服劑、外用劑和經皮製劑，這一區分對於了解用藥依從性模式、優先開發製劑以及整合用於緩釋或靶向給藥技術的醫療設備至關重要。依最終使用者細分，突顯了門診手術中心、居家醫療機構、醫院和專科診所等不同機構的營運需求和採購行為，每種環境都會影響服務設計、人員配置模式和資本投資決策。

全面的區域分析將揭示美洲、歐洲、中東和非洲以及亞太地區獨特的報銷、監管和醫療保健服務趨勢如何影響策略和實施。

區域趨勢對美洲、歐洲、中東和非洲（EMEA）以及亞太地區的臨床實務模式、報銷架構和供應鏈結構都有顯著影響。在美洲，醫療服務的發展趨勢凸顯了門診服務的擴展、打包支付模式的試驗以及與私人保險公司的密切合作，這些因素共同塑造了介入療法和數位療法的普及曲線。該地區的臨床醫生和管理人員通常優先考慮擴充性的門診解決方案和整合式護理路徑，以減少住院次數，同時保持臨床監管。美洲的監管流程和報銷機制既為創新提供了機遇，也為製造商帶來了挑戰，他們必須證明產品的相對價值。

評估產品創新、策略聯盟和對真實世界數據的投資如何影響神經痛治療領域的競爭定位和商業化。

神經痛治療領域主要企業之間的競爭格局取決於器材平台、製劑科學、臨床證據生成和夥伴關係模式的創新。老牌製藥公司正利用其深厚的治療專業知識和分銷網路來保護其核心藥物產品線，同時有選擇地投資於新型製劑和局部/經皮給藥系統，以解決耐受性和依從性方面的挑戰。同時，醫療設備製造商正專注於具有可程式設計、封閉回路型或微創功能的下一代神經調節系統，並透過令人信服的臨床數據和基於服務的交付模式來確立自身地位。

為了在神經痛治療領域實現永續價值，高階主管需要採取明確且優先的行動，以協調產品創新、供應彈性、證據產生和分銷策略。

產業領導者應優先採取一系列切實可行的措施，使臨床創新與永續的經營模式和穩健的營運相契合。首先，實現生產和供應商網路多元化，可降低受地緣政治因素和關稅波動的影響，同時能夠快速回應不斷變化的需求。其次，進行神經調控療法的研究，並投資於整合介入和復健的臨床項目，能夠使產品和服務脫穎而出，並滿足難治性神經痛患者尚未滿足的需求。第三，擴大居家和門診服務體系，既能滿足病患對便利性的需求，又能支持降低系統成本和提高用藥依從性的照護模式。

對用於建構關於神經痛治療方法的實用見解和穩健細分的初級、次級和真實世界證據方法進行綜合概述。

本研究採用整體調查方法，整合了多個資料流，結合了質性研究、系統性二次分析和針對性的真實世界證據評估。一手數據包括對臨床醫生、採購經理、保險公司和醫療設備專家的結構化訪談，旨在了解醫療專業人員的觀點和營運限制。二次分析涵蓋了同行評審文獻、監管指導文件、臨床試驗註冊數據和公共聲明，以闡明臨床標準和報銷趨勢的背景。同時，也利用真實世界使用數據和理賠數據層面的分析來檢驗護理模式並從中獲得細分洞察。在整個研究過程中，資料來源和調查方法始終保持透明。

簡明扼要地總結道，協作創新、基於證據的價值證明和穩健的運作策略對於推進神經痛的治療至關重要。

總之，神經痛治療生態系統正朝著更整合、實證且以病人為中心的照護模式轉變。神經調控療法和標靶遞送技術的進步，以及不斷演變的醫療服務模式和支付方期望，為製造商和醫療服務提供者帶來了機會和實施挑戰。對於尋求持續影響力和商業性可行性的利害關係人相關人員，強調供應鏈韌性、嚴謹的實證實踐和個人化分銷策略的策略性應對至關重要。將臨床創新與支付方可接受的價值提案和可擴展的護理模式相結合，將決定哪些治療方法能夠被廣泛採用並為患者帶來有意義的療效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的神經痛治療市場

  • 非藥物療法
    • 針刺
    • 神經調控療法
    • 物理治療
  • 藥物治療

第9章：神經痛治療市場：依給藥方式分類

  • 注射藥物
  • 口服
  • 外用
  • 經皮吸收

第10章 神經痛治療市場：依藥物類別分類

  • 抗驚厥藥物
  • 抗憂鬱症
  • 局部麻醉劑
  • NSAIDs
  • 鴉片類藥物
  • 外用製劑

第11章：神經痛治療市場：依最終用戶分類

  • 門診手術中心
  • 家庭醫療保健
  • 醫院
  • 專科診所

第12章：神經痛治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：神經痛治療市場：依適應症分類

  • 化療引起的神經痛
  • 糖尿病神經病變
  • 帶狀皰疹後遺症神經痛
  • 三叉神經痛

第14章：神經痛治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：神經痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 神經痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國神經痛治療市場

第18章：中國神經痛治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-F74E250AD635

The Neuralgia Treatment Market was valued at USD 1.35 billion in 2025 and is projected to grow to USD 1.53 billion in 2026, with a CAGR of 13.24%, reaching USD 3.24 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.35 billion
Estimated Year [2026] USD 1.53 billion
Forecast Year [2032] USD 3.24 billion
CAGR (%) 13.24%

An authoritative overview of the multifactorial clinical, technological, and delivery considerations that define the current neuralgia treatment environment

Neuralgia presents a complex clinical challenge that intertwines chronic pain management, evolving device innovation, and diverse pharmacological strategies. In recent years, clinical pathways have broadened to reflect a more integrated approach that encompasses non-pharmacological modalities alongside traditional drug therapies. Clinicians increasingly balance efficacy with tolerability and long-term functional outcomes, prompting a shift in how treatment algorithms are developed and adopted. This introduction frames the current therapeutic environment by examining the interplay between clinical evidence, patient preferences, and health system pressures, and by highlighting the critical drivers that are reshaping practice patterns and commercial priorities.

Moreover, patient-centered care models and technological progress are accelerating changes in care delivery. Telemedicine and decentralized care platforms are altering touchpoints for diagnosis, monitoring, and ongoing management. At the same time, regulatory evolution and reimbursement scrutiny require clearer value demonstration for both established and novel therapies. Consequently, stakeholders must navigate a dynamic landscape where scientific advances, supply chain considerations, and payer expectations jointly influence decision-making. This section establishes the baseline context for deeper analysis across transformational trends, segmentation nuances, regional variation, and strategic implications that follow.

Insights into the converging technological, clinical, and health system forces that are redefining therapeutic pathways and commercial approaches in neuralgia treatment

The neuralgia treatment landscape is undergoing transformative shifts driven by technological innovations, changing care models, and heightened expectations for real-world outcomes. Advances in neuromodulation hardware and software have expanded therapeutic options beyond pharmacology, enabling clinicians to tailor interventions to patient phenotype and pain etiology. Concurrently, improvements in diagnostic precision and biomarker research are informing treatment stratification, allowing earlier intervention and better tracking of therapeutic response. These technological inflections are complemented by an increased emphasis on multimodal regimens that integrate interventional, rehabilitative, and behavioral strategies to achieve durable symptom control and functional recovery.

At the system level, payers and providers are adopting value-based frameworks that prioritize long-term patient outcomes and cost-effectiveness, prompting manufacturers and service providers to generate evidence that extends beyond short-term symptom relief. Patient empowerment and digital health tools are shifting expectations regarding access, monitoring, and therapy personalization, which in turn pressures traditional distribution and engagement models. Finally, supply chain resilience and regional manufacturing strategies have gained prominence; stakeholders now weigh domestic and nearshore production, device lifecycle support, and component sourcing in their operational planning. Taken together, these converging trends are fostering a more responsive, evidence-driven, and patient-centered approach to neuralgia care.

An analytical perspective on how recent tariff measures have reshaped supply chain resilience, procurement strategies, and commercial planning relevant to neuralgia therapies

The introduction of new tariff measures in the United States in 2025 has reverberated across medical product sourcing, procurement strategies, and supply chain design relevant to neuralgia therapies. Import duties and trade adjustments have led stakeholders to reassess supplier portfolios, prioritize cost containment, and explore alternative sourcing strategies to maintain continuity of specialized devices, pharmaceutical ingredients, and adjunctive supplies. Procurement teams are increasingly evaluating total landed cost and resilience metrics, leading some manufacturers and distributors to diversify manufacturing footprints or to renegotiate terms with strategic partners to manage margin pressure while preserving access to critical therapies.

Beyond immediate procurement impacts, tariffs have influenced strategic planning for product launches, clinical trials, and service expansion. Health systems and ambulatory providers are assessing inventory management practices and contracting frameworks to buffer against price volatility. At the same time, some manufacturers have accelerated localization or nearshoring efforts for high-value components and finished devices to mitigate exposure to trade policy shifts. These adaptations are accompanied by intensified dialogue with payers to adjust reimbursement constructs and with regulatory authorities to expedite pathways for domestically produced devices and therapies. In sum, the tariff environment has triggered a recalibration of commercial and operational strategies across the neuralgia treatment ecosystem, emphasizing agility, cost transparency, and supply assurance.

A strategic synthesis of treatment, delivery, end-user, distribution, indication, and drug-class segmentation to reveal differentiated opportunity zones and operational priorities

A multidimensional segmentation lens reveals distinct opportunity zones and operational considerations across treatment types, delivery modes, end users, distribution channels, indications, and drug classes. When analyzed by treatment type, the space differentiates non-pharmacological approaches such as acupuncture, neuromodulation, and physical therapy from pharmacological interventions, each presenting unique adoption levers, reimbursement dynamics, and evidence requirements. Delivery mode segmentation separates injectable, oral, topical, and transdermal options, and this distinction matters for adherence patterns, formulation development priorities, and device integration for sustained-release or targeted delivery technologies. End user segmentation highlights the differing operational needs and procurement behaviors across ambulatory surgical centers, home healthcare providers, hospitals, and specialty clinics, with each setting influencing service design, staffing models, and capital investment decisions.

Distribution channel segmentation underscores the strategic role played by hospital pharmacies, online pharmacies, and retail pharmacies in ensuring patient access, patient education, and medication adherence support. Indication-focused segmentation-comprising chemotherapy-induced neuralgia, diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia-reveals heterogeneity in clinical pathways, comorbidity burdens, and stakeholder engagement needs that should inform targeted clinical development and market access strategies. Finally, drug class segmentation encompassing anticonvulsants, antidepressants, local anesthetics, NSAIDs, opioids, and topical agents clarifies therapeutic positioning, safety and monitoring considerations, and opportunities for combination approaches. Synthesizing these segmentation dimensions facilitates sharper product development priorities, tailored commercial strategies, and nuanced value propositions for distinct stakeholder groups.

A comprehensive regional analysis revealing how distinct reimbursement, regulatory, and care-delivery dynamics in the Americas, EMEA, and Asia-Pacific shape strategy and adoption

Regional dynamics exert a pronounced influence on clinical practice patterns, reimbursement frameworks, and supply chain configurations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, care delivery trends emphasize outpatient expansion, bundled payment experimentation, and robust private payer engagement, which together shape adoption curves for interventional and digital therapies. Clinicians and administrators in this region often prioritize scalable outpatient solutions and integrated care pathways that reduce hospital utilization while maintaining clinical oversight. Regulatory pathways and reimbursement mechanisms in the Americas present both opportunities for innovation and challenges for manufacturers that must demonstrate comparative value.

In Europe, Middle East & Africa, and Asia-Pacific, heterogeneity in healthcare infrastructure, regulatory regimes, and population burden of neuralgia-related conditions drives differentiated strategies. The Europe, Middle East & Africa region tends to emphasize centralized HTA assessment, cross-border innovation diffusion, and public payer negotiation, encouraging manufacturers to build robust clinical dossiers and real-world evidence to support reimbursement. Asia-Pacific markets often combine rapid adoption of digital care models with a strong focus on cost efficiency and domestic manufacturing capabilities, leading to competitive dynamics that favor scalable, low-cost interventions and local partnerships. Across all regions, supply chain localization, regulatory alignment, and culturally informed patient engagement strategies are critical to successful market entry and sustained uptake.

An evaluation of how product innovation, strategic alliances, and real-world evidence investments are shaping competitive positioning and commercialization in neuralgia care

Competitive dynamics among leading companies in the neuralgia treatment space are defined by innovation in device platforms, formulation science, clinical evidence generation, and partnership models. Established pharmaceutical manufacturers leverage deep therapeutic expertise and distribution networks to defend core drug-class franchises while selectively investing in novel formulations and topical or transdermal systems that address tolerability and adherence gaps. Concurrently, medtech firms are focusing on next-generation neuromodulation systems that offer programmable, closed-loop, or minimally invasive capabilities, positioning themselves through compelling clinical data and service-based delivery models.

Smaller specialized companies and startups are accelerating innovation in areas such as targeted delivery technologies, digital therapeutics, and adjunctive rehabilitation tools, often partnering with larger organizations for scale, regulatory navigation, and market access. Strategic alliances between device makers, pharmaceutical companies, and care providers are increasingly common, enabling integrated solutions that combine pharmacological and non-pharmacological elements. Across competitors, emphasis on robust real-world evidence, post-market surveillance, and iterative product improvement has become central to sustaining differentiation in an environment where payers demand demonstrable outcomes and long-term value.

Clear, prioritized actions for executives to align product innovation, supply resilience, evidence generation, and distribution strategies to capture durable value in neuralgia care

Industry leaders should prioritize a set of actionable measures that align clinical innovation with sustainable commercial models and resilient operations. First, diversifying manufacturing and supplier networks will reduce exposure to geopolitical and tariff-driven disruptions while enabling faster responsiveness to demand shifts. Second, investing in neuromodulation research and in clinical programs that integrate interventional and rehabilitative care can differentiate offerings and address unmet needs in refractory neuralgia. Third, expanding capabilities for home-based and ambulatory delivery will meet patient preferences for convenience and support care models that lower system costs and improve adherence.

Additionally, companies should strengthen evidence generation across both randomized and real-world studies to satisfy payer requirements and to support differentiated pricing and contracting strategies. Commercial teams must refine channel strategies to optimize partnerships with hospital pharmacies, online pharmacy platforms, and retail chains, ensuring coherent patient support programs and adherence solutions. Finally, fostering collaborations with specialty clinics, payers, and professional societies will accelerate guideline inclusion and the diffusion of best practices. Collectively, these recommendations promote durable competitive advantage by aligning clinical value with operational resilience and payer-validated outcomes.

A transparent overview of the integrated primary, secondary, and real-world evidence methods used to develop actionable insights and robust segmentation for neuralgia therapies

This research synthesized multiple data streams through an integrated methodology combining primary qualitative inquiry, systematic secondary analysis, and targeted real-world evidence assessment. Primary inputs included structured interviews with clinicians, procurement leaders, payers, and device specialists to capture practitioner perspectives and operational constraints. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public policy statements to contextualize clinical standards and reimbursement trends. In parallel, real-world utilization data and claims-level analyses were used to validate care patterns and to inform segmentation insights, always with attention to data provenance and methodological transparency.

Analytical approaches included cross-segmentation mapping, stakeholder impact assessment, and supply chain scenario planning to identify strategic inflection points and operational risk. Where possible, triangulation methods were applied to reconcile differences between trial evidence, guideline recommendations, and routine practice. Limitations of the methodology-such as regional data variability and evolving regulatory environments-were explicitly acknowledged, and sensitivity checks were performed to ensure that recommendations remained robust under alternative assumptions. Ethical standards and data governance protocols guided all primary engagements, ensuring confidentiality and compliance with applicable research norms.

A concise synthesis underscoring the imperative for coordinated innovation, evidence-based value demonstration, and resilient operational strategies to advance neuralgia care

In closing, the neuralgia treatment ecosystem is moving toward more integrated, evidence-driven, and patient-centric models of care. Technological advances in neuromodulation and targeted delivery, combined with evolving care delivery paradigms and payer expectations, are creating both opportunities and execution challenges for manufacturers and providers. Strategic responses that emphasize supply chain resilience, rigorous evidence generation, and tailored distribution strategies are essential for stakeholders seeking sustained impact and commercial viability. Aligning clinical innovation with payer-acceptable value propositions and scalable care models will determine which therapies achieve broad adoption and deliver meaningful patient outcomes.

Stakeholders that proactively adapt to regional nuances, prioritize partnerships across the care continuum, and commit to transparent outcome measurement will be best positioned to navigate regulatory complexity and competitive pressures. The path forward requires coordinated efforts across R&D, commercial, and operational functions to translate scientific advances into accessible and affordable care. Ultimately, success will be measured by the ability to relieve patient suffering, improve functional status, and integrate neuralgia management into holistic chronic pain strategies that are sustainable for health systems and acceptable to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuralgia Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological
    • 8.1.1. Acupuncture
    • 8.1.2. Neuromodulation
    • 8.1.3. Physical Therapy
  • 8.2. Pharmacological

9. Neuralgia Treatment Market, by Delivery Mode

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Neuralgia Treatment Market, by Drug Class

  • 10.1. Anticonvulsants
  • 10.2. Antidepressants
  • 10.3. Local Anesthetics
  • 10.4. NSAIDs
  • 10.5. Opioids
  • 10.6. Topical Agents

11. Neuralgia Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Healthcare
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Neuralgia Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Neuralgia Treatment Market, by Indication

  • 13.1. Chemotherapy Induced Neuralgia
  • 13.2. Diabetic Neuropathy
  • 13.3. Postherpetic Neuralgia
  • 13.4. Trigeminal Neuralgia

14. Neuralgia Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Neuralgia Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Neuralgia Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Neuralgia Treatment Market

18. China Neuralgia Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Eli Lilly and Company
  • 19.7. GlaxoSmithKline plc
  • 19.8. Grunenthal GmbH
  • 19.9. Johnson & Johnson
  • 19.10. Novartis AG
  • 19.11. Pfizer Inc.
  • 19.12. Sanofi S.A.
  • 19.13. Teva Pharmaceutical Industries Ltd.
  • 19.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEURALGIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEURALGIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY CHEMOTHERAPY INDUCED NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GCC NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 188. G7 NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 189. G7 NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. G7 NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. G7 NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. NATO NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 196. NATO NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NATO NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEURALGIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA NEURALGIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA NEURALGIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA NEURALGIA TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA NEURALGIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA NEURALGIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA NEURALGIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)